When GoodRx (NASDAQ:GDRX) stock debuted in September, its price immediately leaped 60%, peaking at $57 in early October. Regular investors couldn’t have bought shares at any reasonable value, so I wrote GDRX stock off as “yet another high-priced 2020 IPO.”
Source: II.studio / Shutterstock.com
Shares, however, have since declined to a more reasonable $52. At this price, it’s time to take a serious look into this game-changing company.
That’s because, in April, the federal agency...
READ FULL ARTICLE »